Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors
- 2 June 2008
- Vol. 377 (2) , 401-407
- https://doi.org/10.1016/j.virol.2008.04.032
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Targeting Chemokine Receptors in HIV: A Status ReportAnnual Review of Pharmacology and Toxicology, 2008
- Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4Science, 2007
- Escape of HIV-1 from a Small Molecule CCR5 Inhibitor Is Not Associated with a Fitness LossPLoS Pathogens, 2007
- Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activitiesAntiviral Research, 2007
- Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for EntryJournal of Virology, 2007
- Isolation and Characterization of Human Immunodeficiency Virus Type 1 Resistant to the Small-Molecule CCR5 Antagonist TAK-652Antimicrobial Agents and Chemotherapy, 2007
- HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entryVirology, 2006
- Potent Antiviral Synergy between Monoclonal Antibody and Small-Molecule CCR5 Inhibitors of Human Immunodeficiency Virus Type 1Antimicrobial Agents and Chemotherapy, 2006
- The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry InhibitorMolecular Pharmacology, 2005
- Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 InhibitorJournal of Virology, 2004